BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
- Composition of Matter Patent with Expiration Date in 2034 -
LAVAL, QC, April 24, 2017 - BELLUS Health (TSX:BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that the U.S. Patent and Trademark Office has issued U.S Patent. No. 9,598,409, which grants claims covering the composition of matter of BELLUS' lead drug candidate, BLU-5937, and related imidazopyridine compounds, in addition to pharmaceutical compositions comprising BLU-5937 and uses thereof. The patent has an expiration date of 2034, excluding any potential patent term extension. Patent applications with similarly broad claims are currently pending in Europe, Japan, China and other industrialized nations.
- Published: 24 April 2017
- Written by Editor